Gas chromatography coupled to mass spectrometry

Leader

Dra. Rosa del Campo

Personnel

Esther Palacios Gómez (TGS. Lab)

Dra. Ana Moreno Blanco

Contact

gcms@irycis.org

rosacampo(ELIMINAR)@yahoo.com

rosa.campo@salud.madrid.org

  • Gas chromatography-mass spectrometry (GC-MS)

    Gas chromatography-mass spectrometry (GC-MS) is a technique that combines the separation capability of gas chromatography with the sensitivity and selectivity of the mass detector. This combination makes it possible to analyse and quantify trace compounds in complex mixtures with a high degree of effectiveness. This technique is suitable for the separation of volatile and semi-volatile organic compounds.

    The technique consists of volatilising the sample and injecting it into a capillary chromatographic column. Elution occurs by the flow of a mobile phase of an inert gas which transports the analytes through the column. The analytes are reversibly retained as a result of a physical adsorption process. The separated components are eluted from the column and recorded by a MS detector, yielding a mass spectrum representing the abundance of different types of ions as a function of the mass-to-charge ratio of each ion. The use of GC-MS is restricted to the separation of compounds with a molecular weight of less than 1000 and a maximum working temperature of about 400 ºC.

  • Services portfolio

    Currently under development:

    • Method for identification and quantification of Short Chain Fatty Acids and p-cresol in samples of faeces, urine, sputum, cell cultures and others.

    Being optimised:

    • Method for the identification and quantification of ethanol in blood and urine.
    • Method for the identification and quantification of vitamin D in samples of human origin.
    • Method for the identification and quantification of drugs in different types of samples.
  • Equipment
    • Thermofisher GC-MS ISQ76A2203001 - ISQ7610-AEI (single quadrupole) for the analysis of low molecular weight volatile samples.

  • Noteworthy

    Services developed in competitive public research projects such as:

    • ICI21/00012. Transfer of Faecal Microbiota for the Prevention of Complicated and Recurrent Urinary Tract Infections and for the Intestinal Decolonisation of Antibiotic Resistant Multidrug Resistant Bacteria (FEMINAL). 2022-2025. ISCIII
    • PI23/00175. From the Microbiome to the Clinic in Autism Spectrum Disorders: Towards Personalised Interventions. 2024-2026. ISCIII
    • PMP22/00092. MePRAM networking. Precision medicine against antimicrobial resistance. CIBERINFEC
    • MISTAR. Microbiota Intervention Strategies Limiting Selection and Transmission of Antibiotic Resistance burden in the One Health domain. 2022-2024. ISCIII/EU.